Marketing communication

Thematic Certificate · AMC

MGF
BioSciences

Biotechnology and healthcare, at the frontier of tomorrow's medicine.

ISIN CH0566799133 SIX Swiss Exchange · CHF Issuer ZKB
Net asset value · NAV
CHF
Loading…
Investment thesis

Investing in medical innovation.

38
Holdings in the portfolio (active management)
31.6%
Diversified, the portfolio's largest sector
91%
North America, the leading region
Net asset value · Official ZKB NAV

Certificate price

CH0566799133 · ZKB · SIX Swiss Exchange · CHF
CHF
Loading…
1M
3M
6M
1Y
MAX
Loading…
NAV calculated by ZKB (Zürcher Kantonalbank) · Updated daily after market close · Past performance is not indicative of future results.

Biotechnology is no longer a scientific bet. It already accounts for 30% of drug sales worldwide.

MGF BIOSCIENCES

Market context

Medicine moves into the genomic era

Sequencing a full genome, which cost 3 billion dollars in 2000, is heading towards 100 dollars. The 2020 Nobel Prize in Chemistry recognised CRISPR-Cas9, the genetic scissors opening a new generation of therapies. Global health spending is expected to reach 15 trillion dollars by 2030, driven by an ageing population. The American population aged over 65 will double by 2060.

The portfolio covers strategic segments such as medical devices, genetics, rare diseases, diagnostics, oncology and proteins and enzymes, favouring companies with strong potential, often at the frontier of applied research. It thus captures the potential of major medical innovations, carried by scientific advances, demographic change and rising healthcare needs.

Microscopy research, biosciences
Investment universe

Portfolio sector breakdown

Diversified31.6%
Genetics17.3%
Medical devices15.1%
Rare diseases10.9%
Diagnostics9.9%
Top holdings

Portfolio selection

Moderna Inc Top holding · MRNA · NASDAQ · 1-year
+505.3%
09/2512/2503/2606/2609/26
  • Moderna Inc 8.0%
  • Regeneron Pharmaceuticals Inc 6.4%
  • Amgen Inc 5.5%
  • Quest Diagnostics Inc 4.5%
  • Illumina Inc 4.3%
Holdings as of 2026-09-10

4 out of 5 drugs in development come from biotech

Large pharmaceutical groups depend on them. They buy the small companies that invent them.

Certificate characteristics

MGF BioSciences
Thematic certificate

Listed on SIX and hedged into Swiss francs, MGF BioSciences offers diversified exposure to innovative biotechnology companies. It spans strategic segments such as medical devices, genetics, rare diseases, diagnostics, oncology, and proteins and enzymes, favouring high-potential companies often at the frontier of applied research. It thereby captures the promise of major medical innovations, driven by scientific advances, demographic change and rising healthcare needs.

DNA strand, biosciences and health
ISINCH0566799133
IssuerZKB, Zürich
RatingAAA (ZKB)
CurrencyCHF, Hedged
ListingSIX Swiss Exchange
AssetsEquities (30–50 positions)
ManagementActive Management
Buy / SellDaily via issuer
MaturityOpen-ended
Launch11 February 2021
Management fee1.30% p.a.
KIDENFR
TermsheetENFR
ZKB base prospectusDEEN
Why this certificate

3 reasons
to invest

An electrification supercycle is underway. AI, data centres and decarbonisation are creating unprecedented structural demand for electricity production companies.

01
The genomic revolution
CRISPR, gene therapies, messenger RNA: biotech companies led the way on COVID-19 vaccines and are opening access to rare diseases and precision oncology.
02
A health budget that is exploding
15 trillion dollars in 2030, an over-65 population doubling in the United States by 2060: structural demand independent of the economic cycle.
03
A continuous flow of acquisitions
4 out of 5 drugs in development come from biotech research: large pharmaceutical groups buy their growth engines from small companies, crystallising value for the investor.

Would you like to invest in our MGF BioSciences, AMC certificate | MG Finance certificate?

To invest in one of our thematic certificates, you do not need a securities account with MG Finance or with our partner banks. You can simply place an instruction with your own bank, quoting the ISIN, the valor number or the symbol.

Contact us →

MG Finance SA · Av. du Général Guisan 46a, 1009 Pully · +41 21 614 75 75 · research@mgfinance.ch

MG Finance